Business Description
SciClone Pharmaceuticals (Holdings) Ltd
ISIN : KYG4271B1023
Compare
Compare
Traded in other countries / regions
06600.Hong KongSCCPF.USA IPO Date
2021-03-03Description
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 67.72 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 21.6 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.92 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.6 | |||||
| 3-Year EBITDA Growth Rate | 15 | |||||
| 3-Year EPS without NRI Growth Rate | 13.2 | |||||
| 3-Year FCF Growth Rate | -1.7 | |||||
| 3-Year Book Growth Rate | 24.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.6 | |||||
| 9-Day RSI | 79.47 | |||||
| 14-Day RSI | 79.43 | |||||
| 6-1 Month Momentum % | 68.13 | |||||
| 12-1 Month Momentum % | 35.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.94 | |||||
| Quick Ratio | 4.5 | |||||
| Cash Ratio | 3.18 | |||||
| Days Inventory | 86.34 | |||||
| Days Sales Outstanding | 101.32 | |||||
| Days Payable | 68.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.17 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| Forward Dividend Yield % | 2.17 | |||||
| 5-Year Yield-on-Cost % | 2.17 | |||||
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 13.43 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.67 | |||||
| Operating Margin % | 39.84 | |||||
| Net Margin % | 35.55 | |||||
| FCF Margin % | 33.35 | |||||
| ROE % | 36.85 | |||||
| ROA % | 26.73 | |||||
| ROIC % | 77.56 | |||||
| ROC (Joel Greenblatt) % | 150.18 | |||||
| ROCE % | 38.02 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.57 | |||||
| PE Ratio without NRI | 9.57 | |||||
| Price-to-Owner-Earnings | 20.66 | |||||
| PEG Ratio | 0.33 | |||||
| PS Ratio | 3.39 | |||||
| PB Ratio | 3.1 | |||||
| Price-to-Tangible-Book | 3.53 | |||||
| Price-to-Free-Cash-Flow | 10.61 | |||||
| Price-to-Operating-Cash-Flow | 8.97 | |||||
| EV-to-EBIT | 6.24 | |||||
| EV-to-Forward-EBIT | 5.44 | |||||
| EV-to-EBITDA | 6.24 | |||||
| EV-to-Forward-EBITDA | 5.34 | |||||
| EV-to-Revenue | 2.52 | |||||
| EV-to-Forward-Revenue | 1.69 | |||||
| EV-to-FCF | 7.56 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.5 | |||||
| Price-to-Graham-Number | 1.23 | |||||
| Price-to-Net-Current-Asset-Value | 3.73 | |||||
| Price-to-Net-Cash | 6.82 | |||||
| Earnings Yield (Greenblatt) % | 16.03 | |||||
| FCF Yield % | 10.39 | |||||
| Forward Rate of Return (Yacktman) % | 25.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SciClone Pharmaceuticals (Holdings) Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 3,451.546 | ||
| EPS (TTM) (HK$) | 1.881 | ||
| Beta | 0.91 | ||
| Volatility % | 52.9 | ||
| 14-Day RSI | 79.43 | ||
| 14-Day ATR (HK$) | 0.257074 | ||
| 20-Day SMA (HK$) | 17.675 | ||
| 12-1 Month Momentum % | 35.93 | ||
| 52-Week Range (HK$) | 8.75 - 18.28 | ||
| Shares Outstanding (Mil) | 615.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SciClone Pharmaceuticals (Holdings) Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SciClone Pharmaceuticals (Holdings) Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
SciClone Pharmaceuticals (Holdings) Ltd Frequently Asked Questions
What is SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600)'s stock price today?
The current price of HKSE:06600 is HK$18.00. The 52 week high of HKSE:06600 is HK$18.28 and 52 week low is HK$8.75.
When is next earnings date of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600)?
The next earnings date of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) is .
Does SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) pay dividends? If so, how much?
The Dividend Yield %  of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) is 2.17% (As of Today), Highest Dividend Payout Ratio of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) was 0.23. The lowest was 0.21. And the median was 0.23. The  Forward Dividend Yield % of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) is 2.17%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers